Wojciech Poncyljusz

Wojciech Poncyljusz

Auto-generated profile, based on publicly available information

Wojciech Poncyljusz

Department of Diagnostic Imaging and Interventional Radiology, Pomeranian Medical University, 70-204 Szczecin, Poland

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2008 in European Radiology
Verified
Journal Article
Closed access
PDF file
AFAleksander Falkowski
Aleksander Falkowski
WPWojciech Poncyljusz
Wojciech Poncyljusz
GWGrażyna Wilk
Grażyna Wilk
MSMałgorzata Szczerbo-Trojanowska
Małgorzata Szczerbo-Trojanowska

1 October 2006 in Journal of neurosurgery. Pediatrics
Verified
Journal Article
Closed access
LSLeszek M. Sagan
Leszek M. Sagan
IKIreneusz Kojder
Ireneusz Kojder
WPWojciech Poncyljusz
Wojciech Poncyljusz
Endoscopic aqueductal stent therapy has evolved into an important technique in the treatment of a trapped fourth ventricle (TFV). The authors analyzed five cases of symptomatic TFV treated by endoscopic aqueductal stent therapy and, on the basis of intraoperative findings, discuss aspects of TFV formation. Patients' ages ranged from 2 to 17 years (mean 9.2 years). Two patients underwent endoscopy via a coronal bur hole approach and three via a small suboccipital craniectomy. The mean follow-up period was 30 months (range 24-38 months). In four cases, a membrane occluding the orifice of the aqueduct and covering part of the walls of the ventricle was observed. Despite slit ventricles in four cases, there was no intraoperative evidence of aqueduct wall collapse. All procedures were successful, and all patients experienced positive outcomes. In one patient, Parinaud syndrome, rotatory nystagmus, and abducent nerve palsy developed postoperatively; these deficits resolved after a preexisting supratentorial shunt was upgraded. There were no cases of aqueduct reocclusion during the follow-up period. Aqueductal stent therapy is an effective method of TFV treatment. Because it prevents aqueduct reocclusion by chronic inflammatory processes in postinflammatory hydrocephalus, it has been shown to be more efficient than aqueductoplasty alone and to be an important alternative to the placement of a fourth ventricle shunt. Intraventricular processes leading to membrane formation play an important role in occlusion of the cerebral aqueduct orifices and final isolation of the fourth ventricle in postinflammatory hydrocephalus.

1 October 2010 in Journal of Endovascular Therapy
Verified
Journal Article
Closed access
PDF file
LSLuc Stockx
Luc Stockx
WPWojciech Poncyljusz
Wojciech Poncyljusz
MKMarek Krzanowski
Marek Krzanowski
HSHerman Schroë
Herman Schroë
DADominic J. Allocco
Dominic J. Allocco
KDKeith D. Dawkins
Keith D. Dawkins
Purpose: To report the 2-year results of the MELODIE trial, which evaluated the safety and effectiveness of the balloon-expandable Express LD Vascular stent for the treatment of atherosclerotic iliac artery disease. Methods: This prospective, multicenter, single-arm trial enrolled 151 patients (113 men; mean age 60.1±8.4 years) with 163 de novo or restenotic iliac lesions. The primary endpoint, 6-month angiographic mean percent loss of luminal diameter, was compared to an objective performance criterion (OPC) based on published results with the Palmaz stent. Follow-up included ankle-brachial index (ABI) measurement and symptom assessment (Fontaine classification) at discharge, 30 days, and 6, 12, and 24 months. Arteriography was performed at 6 months and computed tomographic angiography (CTA) at 1 and 2 years. Results: The primary endpoint of 6-month mean percent luminal diameter loss was 16.2% (upper 95% confidence boundary of 19.1%) and non-inferior to the 20% OPC (p=0.006). Primary patency was 92.1% at 6 months and 87.8% at 2 years. The rate of major adverse events (MAE) was 6.3% at 6 months and 10.2% at 2 years. Of the 3 event types included in the definition of MAE, only target lesion revascularization occurred; no distal embolization or device- or procedure-related deaths were recorded. The percent of patients with Fontaine stage IIb symptoms or worse improved from 84.1% before the procedure to 16.8% at 2 years (p<0.0001). The 2-year ABI remained significantly improved compared to baseline (0.85 versus 0.63, p<0.0001). Conclusion: The Express LD Vascular stent is safe, effective, and non-inferior to the Palmaz stent for treatment of iliac artery stenosis.

24 November 2011 in Biochemical Genetics
Verified
Journal Article
Open access
PDF file
MRMonika Rac
Monika Rac
JSJanina Suchy
Janina Suchy
GKGrzegorz Kurzawski
Grzegorz Kurzawski
AKAgnieszka Kurlapska
Agnieszka Kurlapska
KSKrzysztof Safranow
Krzysztof Safranow
DCDariusz Chlubek
Dariusz Chlubek
This study investigates potential associations between CD36 gene variants and the presence of risk factors in Caucasians with coronary artery disease (CAD) manifested at a young age. The study group consisted of 90 patients; the men were ≤ 50 years old and the women were ≤ 55 years old. Amplicons of exons 4 and 5 including fragments of introns were analyzed by DHPLC. Two polymorphisms were found: IVS3-6 T/C (rs3173798) and IVS4-10 G/A (rs3211892). The C allele of the IVS3-6 T/C polymorphism was associated with higher prevalence of obesity and diabetes, higher hsCRP, lower Lp(a) serum concentrations, and younger age at myocardial infarction. The A allele of the IVS4-10 G/A polymorphism was associated with older age of myocardial infarction and higher white blood cell count. The functional role of CD36 polymorphisms in CAD development needs further research.

10 December 2020 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
DVDominik F. Vollherbst
Dominik F. Vollherbst
ABA. Berlis
A. Berlis
CMC. Maurer
C. Maurer
LBL. Behrens
L. Behrens
SSStanimir Stefanov Sirakov
Stanimir Stefanov Sirakov
MMMarkus A. Möhlenbruch
Markus A. Möhlenbruch
BACKGROUND AND PURPOSE: Stent-assisted treatment techniques can be an effective treatment option for intracranial aneurysms. The aim of this study was to evaluate the periprocedural feasibility and safety of the new LVIS EVO stent for the treatment of intracranial aneurysms. MATERIALS AND METHODS: Patients with intracranial aneurysms treated with the LVIS EVO in 11 European neurovascular centers were retrospectively reviewed. Patient and aneurysm characteristics, procedural parameters, immediate grade of occlusion, and technical and clinical complications were assessed. RESULTS: Fifty-seven patients with 59 aneurysms were treated with the LVIS EVO device; 57.6% of the aneurysms were incidental; 15.3% were acutely ruptured; 15.3% were recanalized or residual aneurysms; and 11.9% were treated for symptoms other than acute hemorrhage. The most frequent aneurysm locations were the middle cerebral artery (25.4%) and the anterior communicating artery (22.0%). The rate of immediate successful deployment was 93.2%. In 6.8% (n = 4) of cases, additional in-stent angioplasty was needed. The immediate complete occlusion rate was 54.2%, while there was a residual aneurysm in 35.6% and a residual neck in 10.2%. Periprocedural technical complications occurred in 7/59 treatments (11.9%; the most frequent technical complication [n = 3] was thrombus formation), which all resolved completely without clinical sequelae. Postprocedural neurologic complications occurred after 4/59 treatments (6.8%; 2 transient ischemic attacks, 1 minor stroke, 1 major stroke), of which only 1 persistent complication was directly related to the procedure (minor stroke in the vascular territory distal to the stent). CONCLUSIONS: The LVIS EVO stent is a safe, feasible device for the treatment of intracranial aneurysms.

11 April 2013 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
WPWojciech Poncyljusz
Wojciech Poncyljusz
AFAleksander Falkowski
Aleksander Falkowski
KSKrzysztof Safranow
Krzysztof Safranow
MRMonika Rac
Monika Rac
DZDariusz Zawierucha
Dariusz Zawierucha